Meyka Pro banner
Apellis Pharmaceuticals, Inc.

Stay Updated with the Latest Apellis Pharmaceuticals, Inc. APLS News in Real Time

Find APLS news now at Meyka AI. Stay informed with the latest Apellis Pharmaceuticals, Inc. stocks updates, including price news, market analysis, and expert insights.

APLSNASDAQ
HealthcareBiotechnology
$41.03
$0.00(0.00%)
U.S. Market opens in 64h 46m
Denny’s Franchisee Closes 5 Locations in Minnesota, Wisconsin on September 9
📅 19 hours ago

Denny’s Franchisee Closes 5 Locations in Minnesota, Wisconsin on September 9

Denny’s franchisee M15 Inc. closed 5 locations in Minnesota and Wisconsin on September 9, citing unsustainable debt. The chain has shuttered 155 restaurants over two years as it pursues a turnaround.

Read more 12
US Trade Deficit Hits $88.6B in July as AI Chip Imports Surge
📅 7 days ago

US Trade Deficit Hits $88.6B in July as AI Chip Imports Surge

US trade deficit reached $88.6 billion in July 2026, up 24% from June. AI-driven demand for semiconductors and computers pushed imports to record highs while exports fell 2.1%.

Read more 12
Autodesk (ADSK) Stock Falls 4% Despite Q2 Earnings Beat as Fiscal 2027 Guidance Disappoints
📅 14 days ago

Autodesk (ADSK) Stock Falls 4% Despite Q2 Earnings Beat as Fiscal 2027 Guidance Disappoints

Autodesk (ADSK) stock fell about 4% on August 28, 2026, even after the company beat Wall Street estimates in its fiscal second-quarter results. Autodesk posted $2.05 billion in revenue and $3.30 in adjusted EPS, both above expectations. Investors quickly turned their attention to the fiscal 2027 outlook. The strong Q2 numbers were not enough to…

Read more 12
AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial
📅 15 days ago

AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial

AstraZeneca said Thursday its drug Tezspire met all primary and secondary goals in a late-stage trial. The Phase III CROSSING trial tested Tezspire against placebo in eosinophilic oesophagitis (EoE). AstraZeneca developed the drug jointly with Amgen for this chronic inflammatory oesophagus condition. What the CROSSING Trial Showed The Phase III CROSSING trial evaluated two once-every-four-week…

Read more 12
Darline Graham Wins South Carolina GOP Senate Runoff on Trump Backing, August 26
📅 16 days ago

Darline Graham Wins South Carolina GOP Senate Runoff on Trump Backing, August 26

Darline Graham wins South Carolina GOP Senate runoff with Trump endorsement and $827,000 in super PAC spending. Political newcomer will face Democrat Annie Andrews in November.

Read more 12
Canada hits US with C$27.6B tariff counterpunch on August 26
📅 16 days ago

Canada hits US with C$27.6B tariff counterpunch on August 26

Canada imposes C$27.6B in retaliatory tariffs on US goods starting September 8, targeting paper, dairy, steel, and appliances in response to Trump’s 50% tariffs. Kimberly-Clark and Cascades face margin pressure.

Read more 12
Peter Woo’s Family Office Seeks $1 Billion Private Equity Exit
📅 16 days ago

Peter Woo’s Family Office Seeks $1 Billion Private Equity Exit

Peter Woo’s family office is looking to sell $1 billion of private equity stakes including HSG and Vista Equity Partners, as secondary PE sales surge globally.

Read more 12
Cyient Stock in Focus: CCI Approves Acquisition of California-Based Tao Digital Solutions
📅 16 days ago

Cyient Stock in Focus: CCI Approves Acquisition of California-Based Tao Digital Solutions

Cyient Stock will stay in the spotlight after the Competition Commission of India cleared its acquisition of TAO Digital Solutions Inc. The regulator confirmed approval for a 100% share capital acquisition on August 25, 2026. Cyient’s market capitalization stood at ₹10,212.85 crore as of the same date.  The all-cash deal, first announced in May 2026,…

Read more 12
TVS Supply Chain Solutions Rallies 9% to ₹131 on Strategic MoU and Equity Stake by Japan’s Sankyu
📅 18 days ago

TVS Supply Chain Solutions Rallies 9% to ₹131 on Strategic MoU and Equity Stake by Japan’s Sankyu

TVS Supply Chain Solutions witnessed strong buying momentum on August 24, 2026. Shares surged nearly 9% to trade around ₹131. Investors reacted positively to the strategic Memorandum of Understanding signed with Japan-based Sankyu Inc. Under this alliance, Sankyu plans to acquire a 0.5% equity stake in TVS Supply Chain Solutions.  The deal combines global engineering…

Read more 12

APLS News FAQ